๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข EPS: $2.06 (Est. $1.94) โ
โข Revenue: $6.0B (Est. $6.00B) ๐ฐ
โข GAAP EPS: $1.45
โข Operating Cash Flow: $1.3B
โข Free Cash Flow: $1.1B
โ
๐ ๐๐ฎ๐ข๐๐๐ง๐๐
โข FY EPS: $8.35โ$8.55 (Est. $8.40) โ
โข Core Revenue Growth: 3%โ6%
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Adjusted EPS beat driven by productivity and mix
โข Revenue flat vs expectations despite modest YoY growth
โข Continued recovery in Life Sciences and Bioprocessing
โข Cepheid weakness from softer respiratory season
โข Announced Masimo acquisition to expand patient monitoring
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
โOur team executed well in the first quarter, delivering nearly 10% adjusted EPS growth while continuing to drive innovation and productivity gains.โ